Sarepta resumes shipping of gene therapy Elevidys to patients who can walk – Reuters
- Sarepta resumes shipping of gene therapy Elevidys to patients who can walk Reuters
- Updated: Sarepta would have to conduct new studies to get back on market, FDA official says Endpoints News
- Sarepta will resume gene therapy shipments after FDA review of recent patient death Bowen Island Undercurrent
- FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt statnews.com
- Third patient dies after receiving a Sarepta gene therapy Progress Educational Trust